NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
Vancouver, Canada. March 8, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency (“EMA”) has granted Orphan Designation for the treatment of spinal cord injury (“SCI”) to NVG-291, […]
NervGen Pharma Provides Regulatory Update on Development Program for NVG-291 / Plans to Dose First Human Subjects in Phase 1 in Q2 2021
Vancouver, Canada. March 4, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided a regulatory program update for NVG-291, a specific and selective protein tyrosine phosphatase sigma (“PTPσ”) inhibitor being developed for the treatment of spinal […]
Oh Hello Alzheimer’s – A Caregiver Spotlight
By Codi Darnell March 2, 2021 Lisa and Peter Marshall have a love story that spans 20 years. For eight of those years, they sustained a long-distance relationship so as not to disrupt their children’s lives – crossing states to see each other every weekend they could manage. Finally, in August of 2009, they said […]
Perspective is a New Diagnosis
By Codi Darnell February 16, 2021 It only takes a few words to tip a life onto its axis, “You have [insert your diagnosis here]”. Whether it’s your own condition or that of a loved one, suddenly life has a definitive before and after. Your memories are framed in a new knowing and your future […]
Meet Codi Darnell: Living that Mom, Wife and Wheelchair Life
By Codi Darnell Nancy Thompson, Interviewer February 2, 2021 Life is unpredictable, but at 28 years old, Codi Darnell felt like she had life figured out. She had an amazing husband, three wonderful children and a great life. Then, in a single moment, everything came crashing down. On March 10, 2016, Codi suffered a fall […]
NervGen Pharma Adds Alzheimer’s Disease Patient Cohort to its Phase 1 Clinical Trial Program
Vancouver, Canada. January 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer’s disease patient cohort to its Phase 1 clinical trial program for its lead […]
NervGen Pharma Establishes Alzheimer’s Disease Scientific Advisory Board
Vancouver, Canada. January 26, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer’s Disease Scientific Advisory Board (“AD-SAB”) with the appointment of four world-class scientists and clinical […]
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, Canada, January 5, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate […]
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, Canada. December 15, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited (“Novotech”), a leading full-service contract research organization (“CRO”) in Asia-Pacific, for its upcoming Phase […]
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, Canada. November 19, 2020 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020. Paul Brennan, NervGen’s President & CEO, stated, “During […]